Showing results (1-10 of 450) with videos related to
Sort By:
Pageof 45
Expert Opinion on Therapeutic Targets|April 27, 2017
Targeting LRRK2 in Parkinson's disease: an update on recent developmentsSharon L Chan, Eng-King TanExpert Opinion on Therapeutic Targets|November 12, 2013
Targeting leucine-rich repeat kinase 2 in Parkinson's diseaseSharon L Chan, Dario C Angeles, Eng-King TanMolecular Brain|April 24, 2014
MAP1B rescues LRRK2 mutant-mediated cytotoxicitySharon L Chan, Ling-Ling Chua, Dario C Angeles, et al.Journal of Child Neurology|February 12, 2005
Psychogenic tics: diagnostic value of the placebo testEng-King TanAnnals of the Academy of Medicine, Singapore|December 13, 2006
Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's diseaseEng-King TanJournal of Neurology|November 30, 2006
Restless legs syndrome and Parkinson's disease: is there an etiologic link?Eng-King TanExpert Review of Neurotherapeutics|October 9, 2009
Dopamine agonists and their role in Parkinson's disease treatmentEng-King TanNPJ Parkinson'S Disease|February 19, 2025
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical dataBin Xiao, Eng-King TanTrends in Molecular Medicine|July 27, 2023
Targeting α-synuclein and c-Abl in Parkinson's diseaseBin Xiao, Eng-King TanTrends in Neurosciences|October 7, 2022
Thalamic pathways mediating motor and non-motor symptoms in a Parkinson's disease modelBin Xiao, Eng-King TanPageof 45